adaptive radiation therapy

Overview

Adaptive radiation therapy (ART) is a radiotherapy approach in which the treatment plan is modified during the course of treatment to account for changes in tumor size, shape, position, or surrounding normal anatomy. The goal is to maintain target coverage and dose conformity while reducing exposure to organs at risk as anatomy evolves over time. In practice, ART is especially relevant for tumors in sites where motion, weight loss, tumor regression, or other treatment-related changes can substantially alter the delivered dose distribution.

Biologically and clinically, ART is part of the broader effort to improve the precision of radiation therapy and to better match treatment delivery to the patient’s changing anatomy and response. It is used in settings such as lung cancer and other solid tumors where inter-fraction variation can affect both efficacy and toxicity. Recent work also places ART within a wider landscape of radiotherapy optimization, including integration with immunotherapy, use of artificial intelligence, and quantitative imaging or dosimetric tools to predict when adaptation is needed.

Focus of Latest Publications

Recent publications show ART being studied primarily as a strategy to improve dose delivery, target coverage, and clinical decision-making in lung cancer, especially locally advanced non-small cell lung cancer (LA-NSCLC). A prospective evaluation of ART in LA-NSCLC assessed a “traffic light” adaptation protocol focused on target coverage, protocol performance, and patient outcomes. This indicates that ART is being operationalized through structured decision rules to determine when replanning is warranted during treatment.

A related study developed a delta-based multi-omics model to predict adaptive radiotherapy benefit in patients with NSCLC during carbon-ion radiotherapy. The stated aim was to build a decision-support tool to estimate ART demand before treatment, suggesting that ART is increasingly being linked to predictive modeling rather than relying only on on-treatment anatomical changes. This aligns with broader use of computational tools, bioinformatics approaches, and artificial intelligence in radiotherapy planning.

Several studies in the provided context address the clinical and technical environment in which ART is used. One investigation focused on integrated machine learning risk modeling for predicting radiation pneumonitis in lung cancer patients with interstitial lung disease, highlighting the importance of toxicity prediction in patients receiving radiotherapy. Another study examined factors associated with rectal spacer use in prostate cancer patients receiving radiation therapy, reflecting the broader theme of adapting treatment to reduce normal tissue dose. Although not ART-specific, such work supports the same clinical objective: improving therapeutic ratio through individualized planning and mitigation of toxicity.

The recent literature also places ART within the expanding field of radiotherapy-immunotherapy combinations. Multiple studies describe radiotherapy as capable of shaping local and systemic immune responses, inducing immunogenic cell death, and contributing to antitumor immunity through pathways such as cGAS-STING. Publications on radiotherapy combined with immune checkpoint inhibitors, PD-1/PD-L1 blockade, lenvatinib, AAV-iIL12, dendritic cell-mediated antigen priming, and other immunostimulatory strategies emphasize that radiotherapy is increasingly viewed as a biologically active partner in combination therapy. While these studies are not all directly about ART, they provide context for why adaptive approaches may matter: if radiotherapy is being combined with immunotherapy, maintaining accurate dose delivery over time becomes even more important for both efficacy and safety.

Other publications in the set address response assessment and toxicity after radiotherapy, including brain tumor response imaging, acute radiation dermatitis, oral mucositis, and radiation pneumonitis. These studies reinforce the clinical need for adaptation by showing that treatment effects and adverse events can vary substantially across patients and treatment sites. In addition, work on radioresistance, DNA damage repair, HDAC6, STAT1, C1QBP, and other mechanisms underscores the biological complexity of radiotherapy response, which ART seeks to address at the level of treatment delivery rather than tumor biology alone.

Key Publications

• May Prospective evaluation and clinical outcomes of adaptive radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). (Acta oncologica (Stockholm, Sweden), 2026, PMID 42200217): "This study aims to evaluate a traffic light adaptation protocol regarding target coverage, protocol performance and patient outcomes."
• May Nanomechanical Single-Cell Profiling Reveals Mechanical Dormancy Underlying Radiation Resistance in Polyploid Giant Cancer Cells. (ACS nano, 2026, PMID 41955234): "Radiation therapy induces DNA damage primarily through reactive oxygen species, leading to cancer cell apoptosis."
• May Development and Evaluation of Tofacitinib Tablets with Comparative Dissolution and Pharmacokinetic Studies in Beagle Dogs. (AAPS PharmSciTech, 2026, PMID 42091763): "In this study, a Tofa free base tablet (WT2) prepared by wet granulation was evaluated in Beagle dogs and compared with a marketed reference tablet (RT)."
• May Outcomes of early versus late radiotherapy in grade 2 meningiomas: a National retrospective analysis from the TROD neuro-oncology group. (Journal of neuro-oncology, 2026, PMID 42086919): "This multicenter study compared long-term outcomes of early RT versus late RT, focusing on progression-free survival (PFS), overall survival (OS), and tumor-related mortality."
• May Management of persistent and recurrent Cushing's disease: Efficacy of repeat transsphenoidal surgery. (Endocrine, 2026, PMID 42081125): "In addition to medical treatment, radiation therapy and bilateral adrenalectomy, repeat TSS must also be considered."
• May C1QBP-STAT1 Interaction Promotes Activation of the c-Myc-CHK1/CHK2 Signaling Axis and Radioresistance in Lung Cancer. (Molecular cancer research : MCR, 2026, PMID 41642096): "One of the primary factors contributing to the failure of radiotherapy is the resistance of cancer cells to radiation."
• May A delta-based multi-omics model to predict adaptive radiotherapy benefit in patients with non-small cell lung cancer during carbon-ion radiotherapy. (Physics in medicine and biology, 2026, PMID 42031010): "This study aimed to develop a decision-support tool to estimate ART demand before treatment."
• May Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. (Cancer cell, 2026, PMID 41875889): "Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors."
• May A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). (Japanese journal of clinical oncology, 2026, PMID 41615067): "Metastasis-directed therapy (MDT) has recently been established to incorporate local therapy, such as radiotherapy and surgery, for distant metastases."
• May Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41855781): "Androgen-deprivation therapy (ADT) plus radiotherapy is a standard of care for men with high-risk localized prostate cancer (PC)."